The Bamlanivimab+Etesevimab are anti-SARC-COVID-2 monoclonal antibodies which have received Emergency Use Authorization (EUA) from US FDA as well as conditional use approval from the MoHP, Department of Drug Administration (DDA) in Nepal.
Latest Public Health Jobs
Latest Posts
- Nepal Public Health Conference 2025
- World Oral Health Day 2025: A Happy Mouth is a Happy Mind
- Report and Action Plan of the Health Insurance Reform Advisory Committee, 2024
- World Kidney Day 2025: Are Your Kidneys OK? Detect early, protect kidney health
- World Glaucoma Week 2025: Uniting for a Glaucoma-Free World
Thanks for visiting us.
Disclaimer: The resources, documents, guidelines, and information on this blog have been collected from various sources and are intended for informational purposes only. Information published on or through this website and affiliated social media channels does not represent the intention, plan, or strategies of an organization that the initiator is associated with in a professional or personal capacity, unless explicitly indicated.
If you have any complaints, information, or suggestions about the content published on Public Health Update, please feel free to contact us at blog.publichealthupdate@gmail.com.
#StayUpdated
